Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic malignancies and measurable residual disease monitoring. It is available to Tempus’ Life Sciences partners to support exploratory research and clinical development programs. It has been clinically validated in multiple myeloma and other plasma cell dyscrasias, and is available for research use only across other indications.

GenoPredicta integrates flow cytometry for precise tumor cell detection and enumeration with whole‑genome sequencing to deliver a comprehensive analysis of the cancer genome. The workflow identifies genetic alterations—including single‑nucleotide variants and insertions/deletions, copy‑number variants, and structural variants—from as few as 50 tumor cells, corresponding to a sensitivity as low as one in a million cells. This level of sensitivity is intended to expand testing eligibility to cases with low tumor burden.

The assay is designed to aid in diagnosis, risk classification, and the identification of therapy resistance mechanisms from a single workflow. It may be performed on peripheral blood or bone marrow, with the goal of providing deep molecular insights relevant to hematologic disease biology. The collaboration focuses on expanding access for research and development applications across the Life Sciences sector.

"GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100% concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies."

“By joining forces with Tempus, we are delivering unprecedented sensitivity and clarity to researchers - enabling the potential for earlier detection, smarter treatment decisions, and a deeper understanding of disease biology from a single assay,” said Brian McKernan, CEO of Predicta Biosciences. “This partnership with Tempus will help accelerate market adoption and the utility of our tests in order to optimize clinical trials."

Related Links
Tempus AI
Predicta Biosciences